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The proapoptotic activity of these unbound receptors -so far mainly observed in vitro -has been suggested to be a mechanism for eliminating tumor cells that would develop when tumor cells proliferate in an environment with constant and limited ligand availability or migrate toward tissues devoid of ligand during the metastatic process. Losing the proapoptotic activity of their dependence receptors would be advantageous for the tumor cells ' survival and could be achieved by at least three mechanisms. First, expression of the dependence receptor could be reduced. The existence of this mechanism is supported by the fact that the expression of DCC and UNC5H genes is reduced in many tumors ( 16 -18 ) and that, in mice, inactivation of UNC5H3 leads to intestinal tumor progression ( 19 ) . Second, downstream death signaling could be shut down. UNC5H2 proapoptotic activity relies on the binding of UNC5H2 to the DAP-kinase ( 15 ), a protein demonstrated to be involved in metastasis regulation and whose expression is reduced in human malignancies ( 20 , 21 ) . The model described above predicts that a gain of netrin-1 expression would represent a third mechanism whereby survival of tumor cells would be enhanced. This third selective advantage has been observed in metastatic breast cancer ( 22 ) , and the underlying mechanism may suggest potential therapeutic approaches because extracellular modulation of interaction between netrin-1 and its receptors may trigger tumor cell apoptosis and could be associated with inhibition of tumor growth.
Lung cancer is the leading cause of cancer-related deaths, and the worldwide incidence of adenocarcinoma appears to be increasing ( 23 ) . Conventional therapeutics often have limited effect on lung cancer progression, and the overall 5-year survival is only 15% ( 24 ) . We investigated whether a selective advantage for lung cancer cells due to alterations in netrin-1 dependence could be observed in this pathology by analyzing the netrin-1 level in a panel of human non -small cell lung cancer (NSCLC) cell lines and by determining whether interference with netrin-1 is associated with NSCLC cell death in vitro and tumor regression in a xenograft mouse model.
Patients, Materials, and Methods

Cell Lines, Transfection Procedures, and Reagents
Human lung cancer cell lines, including H358, H460, H322, H522, and H1435 cell lines, were cultured in RPMI 1640 Glutamax medium (Gibco; Invitrogen, Inc., Carlsbad, CA) containing 10% fetal bovine serum. The A427 human cell line was cultured in Dulbecco ' s modified Eagle's medium (Gibco; Invitrogen) containing 10% fetal bovine serum. Human lung cancer cell lines were transfected by use of Lipofectamine reagent (Invitrogen) for plasmids or Lipofectamine 2000 reagent (Invitrogen) for small interfering RNA (siRNA). Netrin-1 was obtained from Apotech Corp./Axxora (Lausanne, Switzerland) and was used at a concentration of 150 ng/mL in all experiments presented. General caspase inhibitor z-VAD-fmk (benzyloxycarbonyl-VAD-fluoromethyl ketone) and specific caspase inhibitors DEVD-fmk (caspase-3), IETD-fmk (caspase-8), and LEHD-fmk (caspase-9) (R&D Systems, Minneapolis, MN) were, respectively, used at 1 and 10 µ M.
Human Lung Tumor Samples
Frozen tissues, as well as paired tumor and distant normal lung tissues, were retrieved from the Tumor Bank. Tumors were classified according to histopathologic World Health Organization 2004 classification of lung tumors ( 25 ) . Of 97 tissues analyzed, 92 samples were interpretable immunohistochemically including 45 adenocarcinomas and 47 squamous cell carcinomas. The 25 frozen samples that were used for mRNA extraction and quantitative reverse transcription -polymerase chain reaction (Q-RT-PCR) were required to contain more than 70% tumor cells. The use of all patients ' tissues was according to French laws and regulations.
Plasmid Constructs, siRNA, and DCC-5Fbn Production The dominant negative mutants for UNC5H (pCR-UNC5H2-IC-D412N) and DCC (pCR-DCC-IC-D1290N) have been previously described ( 8 , 9 ) . Caspase-8 and caspase-9 dominant negative encoding constructs were previously described ( 22 ) . The plasmid Ps974-DCC-5Fbn that allows bacterial expression of the fifth fibronectin type III domain of DCC was obtained by inserting a Pst I/ Bam HI DNA fragment generated by polymerase chain reaction with the already described plasmid pDCC-CMV-S ( 8 ) as a template. DCC-5Fbn production was performed as follows. Briefly, BL21 cells were forced to express DCC-5Fbn by isopropyl B Ϫ D-1-thiogalactopyranoside induction, and the BL21 lysate was subjected to affinity chromatography with Flag-sepharose (Sigma, St Louis, MO). For cell culture use, scrambled and netrin-1 siRNAs were designed by Santa Cruz (Santa Cruz, CA) as a pool of three target-specific siRNAs of 20 -25 nucleotides.
CONTEXT AND CAVEATS
Prior knowledge
The availability of netrin-1, a ligand for proapoptotic dependence receptors, had been demonstrated to play a role in tumor survival in some cancers.
Study design
The expression of netrin-1 was measured in non -small cell lung cancers (NSCLC). The activity of netrin-1 and that of individual dependence receptors in cancer cells derived from NSCLCs was modulated using small interfering RNAs and other methods, and the effects of these modifications on apoptosis in vitro, and the growth in mice of tumors derived from these cells, were measured.
Contribution
This work demonstrated the presence of substantial levels of netrin-1 in a large fraction of human NSCLC tumor samples and suggested that the growth of some NSCLCs may depend on the interaction of netrin-1 and its dependence receptor(s).
Implications
Targeting netrin-1 or its dependence receptor(s) might represent a potential approach for treating NSCLC.
Limitations
These studies were confined to cell lines and animal models that may not be adequate models for NSCLC in humans. For use in mice, a single netrin-1 siRNA was produced (SigmaProligo, St Louis, MO).
From the Editors
Cell Death Assays
For cell death assays, 1.8 × 10 5 cells were cultured in medium without serum and were treated (or not) with DCC-5Fbn (0.5 µ g/mL) or transfected with siRNA with Lipofectamine 2000 (Invitrogen ). Cell death was analyzed by trypan blue staining, as previously described ( 8 ) . The extent of cell death was calculated as the percentage of trypan blue -positive cells in each cell population. Apoptosis was monitored by measuring caspase-3 activity as described previously ( 8 ) , by use of the Caspase-3/CPP32 Fluorometric Assay Kit (Gentaure Biovision, Brussels, Belgium). Cell survival was also measured 48 hours after treatment with the Vybrant MTT (dimethylthiazol diphenyltetrazolium) assay kit (Molecular Probes; Invitrogen), in 2.0 × 10 4 cells that were treated (or not) with DCC5Fbn (0.5 µ g/mL) in 96-well plates, according to the manufacturer's instructions. For detection of DNA fragmentation on cryosections, terminal deoxynucleodityltransferase -mediated dUTP-biotin nick end labeling (TUNEL) was performed with terminal deoxynucleodityltransferase at 300 U/mL and 6 µ M biotinylated dUTP (Roche Diagnostics, Meylan, France), as previously described ( 26 ) .
Quantitative Reverse Transcription -Polymerase Chain Reaction
To assay netrin-1, DCC and/or UNC5H receptors, and DAPK1 expression in human lung normal and tumoral tissue and/or in lung cancer cell lines, total RNA was extracted from biopsy specimens and/or cells with the Nucleospin RNAII kit (MachereyNagel, Düren, Germany), and 1 µ g of RNA was reverse transcribed by use of the iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA). Real-time Q-RT-PCR was performed on a LightCycler 2.0 apparatus by use of the LightCycler FastStart DNA Master SYBR Green I kit (Roche, Basel, Switzerland). Reaction conditions for optimal amplification and primer selection were determined as described above. The ubiquitously expressed human hypoxanthine -guanine phosphoribosyltransferase (HPRT), ␤ -actin, and 18S and 28S ribosomal RNA genes, which showed the least variability in expression between normal and tumor lung tissues, were used as internal controls. The sequences of the primers are shown in Supplementary Table 1 (available online).
Immunohistochemistry
Xenograft tumors were embedded in 7.5% gelatin with 0.12 M sucrose, and 10-µ m sections were prepared. For immunohistochemistry on H358 and H460 cells, 1.0 × 10 5 cells were centrifugated on cover slips with a cytospiner (Shandon Cytospin 3; Thermo Scientific, Waltham, MA). To block endogenous peroxidase activity, the slides were incubated in 2% hydrogen peroxide in phosphate-buffered saline (PBS). The slides were then incubated at room temperature for 1 hour with an antibody against human netrin-1 (dilution 1:200; R&D Systems), or cleaved human caspase-3 (dilution 1:250; Cell Signaling, Danvers, MA). After rinsing in PBS, the slides were incubated with a biotinylated secondary antibody conjugated to a streptavidin -peroxidase complex (Vectastain ABC; Vector Laboratories, Servion, Switzerland). Bound antibody was detected by use of 3,3-diamino benzidine.
For immunohistochemistry on lung tumor tissue samples, the anti-netrin-1 antibody (AB2 rabbit polyclonal antibody; Calbiochem, EMD Biosciences, San Diego, CA) was used at a 1:50 dilution on frozen tissue sections, which had been fi xed with acetone. Secondary and tertiary antibodies were applied by use of Zymed Histostain Plus (Zymed Laboratories, San Francisco, CA). The immunostaining score was calculated by multiplying the percentage of positive tumor cells by an intensity value that could vary from 0 to 3, with 0 being no staining, 1 being weak staining, 2 being moderate staining, and 3 being strong staining. The immunostaining score could thus range from 0 to 300. A median score of 60 was used as the cutoff point for negative (score of <60) vs positive (score of ≥ 60) samples. Preabsorption of anti-netrin-1 antibody with a recombinant protein netrin-1 (provided by Calbiochem) was used as a control. Specifi city of staining was also controlled by use of preimmune rabbit serum in place of netrin-1 antibody. Immunostaining scores were evaluated in blinded fashion.
In Situ Hybridization
Specific digoxigenin (DIG)-labeled sense and antisense RNA probes corresponding to human NTN1 complementary DNA (cDNA) were generated as described in the "DIG RNA Labeling Kit" (Roche). In situ hybridization was performed on 10-µ m cryostat sections of normal and tumor tissue from the same patient. Briefly, fresh slides were fixed in 4% paraformaldehyde and then treated with 0.25% acetic anhydride in 0.1 M triethanolamine for 10 minutes. They were then dehydrated with a series of graded ethanol solutions, and hybridization was performed at 56°C for 15 hours. Slides were washed in saline -sodium citrate (SSC, 3 M NaCl, 0.3 M sodium citrate, pH 7) at 55°C, followed by a formamide wash at 55°C and SSC washes at 37°C. DIG-labeled RNA hybrids were reacted with alkaline phosphatase -conjugated anti-DIG antibodies (Roche). The reaction product was visualized by incubating the sections with nitro-blue tetrazolium chloride and 5-bromo-4-chloro-3-indolylphosphate (Roche) overnight at room temperature.
Xenograft of Human Tumor Cells in nude Mice
Five-week-old (20 -22 g [body weight]) female athymic nu/nu mice were obtained from Charles River. The mice were housed in sterilized filter-topped cages and maintained in a pathogen-free animal facility. H358 or H460 cells were implanted by subcutaneous injection of 5.0 × 10 6 cells in 200 µ L of PBS into the left flank of the mice to make one tumor per mouse. When tumors reached a volume of approximately 60 mm 3 in approximately 5 days after injection, 20 µ g of DCC-5Fbn in 35 µ L (n = 12 H358-xenografetd mice and n = 4 H460-xenografted mice) or an equal volume of PBS (n = 13 H358-xenografetd mice and n = 4 H460-xenografted mice) was injected daily into the tumor for 25 days. In other experiments, 3 µ g of siRNA targeting netrin-1 (n = 6 H358-xenografetd mice and n = 5 H460-xenografted mice) or scrambled siRNA (n = 6 H358-xenografetd mice and n = 5 H460-xenografted mice) was injected intraperitoneally each day for 14 days. Tumor sizes were measured with a caliper. The tumor volume was calculated with the formula v = 0.5 ( l × w
Statistical Analysis
The statistical significance of differences between groups was evaluated by the paired Student t test or the Mann -Whitney test. Mean values for all outcome variables are presented with 95% confidence intervals. Data presented are representative of at least three independent experiments. All statistical tests were two-sided, and P values less than .05 were considered to be statistically significant.
Results
Netrin-1 Expression in Human NSCLC Tumors
We first analyzed netrin-1 expression in a panel of 92 NSCLC tumors, including 45 adenocarcinomas and 47 squamous cell carcinomas, by immunohistochemistry with an antibody against netrin-1. Netrin-1 expression in normal bronchial and alveolar epithelial cells was absent or low ( Figure 1, A ) , but both tumor types expressed high levels of netrin-1. Netrin-1 immunostaining was detected in the cytoplasm and in both apical and basal membranes, with 43 of the 92 NSCLC samples (47%) showing high netrin-1 staining. No statistically significant differences were observed in staining intensity between carcinomas at different stages (I -IV) ( Supplementary Table 2 , available online). Netrin-1 expression was more frequent and more intense in adenocarcinomas (60% of samples were positive, with a median score of 100) than in squamous cell carcinomas (34% positive samples with a median score of 50). In situ hybridization to detect netrin-1 mRNA identified a substantial level of netrin-1 mRNA in the epithelial tumor cells, but netrin-1 mRNA levels were undetectable or very low in the stroma cells, indicating that netrin-1 may be produced by tumor cells ( Figure 1, B ) .
To quantify the expression of netrin-1 and its receptors, we determined the level of mRNAs encoding netrin-1 and its dependence receptors DCC, UNC5H1, UNC5H2, UNC5H3, and UNC5H4 by Q-RT-PCR in a panel of 25 lung carcinomas, including 14 adenocarcinomas and 11 squamous cell carcinomas, as well as in adjacent normal tissues that were at least 5 cm from the tumor. Netrin-1 expression was more than 4-fold higher in lung tumors than in adjacent normal tissue, with the mean number of netrin-1 cDNAs, relative to HPRT cDNAs, in tumor tissue being 23.65 and that in normal adjacent tissue being 5.00 (difference = 18.65, 95% confi dence interval [CI] = 15.65 to 21.54, P = .017). Netrin-1 overexpression relative to normal tissue was observed in 19 of the 25 tumors (76%), with 13 (52%) of them showing more than a 3-fold increase in netrin-1 content relative to normal tissue. With the exception of one patient (data not shown), tumors overexpressing netrin-1 also expressed at least two of the netrin-1 dependence receptors. Mean DCC expression was decreased in 23 of the 25 tumors (92%), with the mean number of DCC cDNAs, relative to HPRT cDNAs, in tumor tissue being 3.72 and that in normal adjacent tissue being 16.25 (difference = 12.53, 95% CI = 10.31 to 14.75, P < .001), in agreement with previous results in lung cancer and other malignancies ( 27 ) . At least two of the UNC5H receptors were always present in each tumor with high netrin-1 expression, but the levels of UNC5H receptors were not statistically signifi cantly different between normal and tumor tissues ( Figure 1, C ) .
We next screened 25 human NSCLC and small cell lung cancer cell lines for netrin-1 expression by Q-RT-PCR. Although some lung tumor cell lines had absent or low levels of netrin-1 expression, other lung cancer cell lines showed high netrin-1 expression ( Supplementary Figure 1 , available online). Two NSCLC cell lines, H358 and H460, that expressed different levels of netrin-1 were studied further. H358 cells were selected because of their relatively high level of netrin-1 expression, and H460 cells, with low level of netrin-1 expression, were picked as controls. Similar to the results in human tumor specimens, H358 cells expressed barely detectable levels of DCC receptor but higher levels of UNC5H receptors ( Figure 1, D ) . To determine whether netrin-1 mRNA expression in H358 cells was associated with endogenous netrin-1 production, we determined the level of netrin-1 protein in H460 and H358 cells by use of immunohistochemistry with an antibody against netrin-1. Netrin-1 -specifi c staining was detected in the cell membrane of most H358 cells ( Figure 1, E ) , but no specifi c staining for netrin-1 was detected in H460 cells. Similar results were obtained with two other cell lines with high levels of netrin-1 mRNA (H322 and A427) and two cell lines with low levels of netrin-1 mRNA (H522 and H1435) ( Supplementary Figure 1 , B and C, available online). Thus, the high netrin-1 expression that we observed in NSCLC primary tumors was also found in some of the lung cancer cell lines examined.
Netrin-1 Autocrine Expression and Lung Tumor Cell Death
To investigate whether the netrin-1 expression observed in netrin-1 -high cells is a selective advantage for survival, netrin-1 expression was reduced by RNA interference. Transfection of H358 cells with netrin-1 siRNA was associated with a reduction in netrin-1 mRNA of 58%, with the mean percentage of netrin-1 expression in scrambled siRNA -treated cells, compared with untreated cells, being 93% and that in netrin-1 siRNA -treated cells being 35% (difference = 58%, 95% CI = 52% to 63%, P = .007) ( Figure 2, A ) . The reduction in expression was associated with a decrease in netrin-1 protein expression, as detected by immunohistochemistry ( Figure 2, B ) . Although transfection of H358 cells with scrambled siRNA did not affect their survival, as measured by the trypan blue exclusion assay, netrin-1 siRNA transfection was associated with H358 cell death, with the percentage of cell death in untreated cells being 15%, that in scrambled siRNA -treated cells being 18%, and that in netrin-1 siRNA -treated cells being 40% (difference between scrambled siRNA -and netrin-1 siRNA -treated cells = 23%, 95% CI = 11% to 34%, P = .007) ( Figure 2, C ) . In H460 cells, expressing low levels of netrin-1, survival was not affected by netrin-1 siRNA treatment ( Figure 2, C ) . To determine whether this increase in cell death was due in part to induction of apoptotic cell death, caspase-3 activity was measured in response to netrin-1 siRNA treatment. As shown in Figure 2 , D , apoptotic cell death was induced by netrin-1 siRNA treatment in H358 cells, with caspase-3 activity, normalized to that in untreated cells, being 0.96 in scrambled siRNA -treated cells and 2.44 in netrin-1 siRNAtreated cells (difference in apoptotic cell death between scrambled siRNA -and netrin-1 siRNA -treated cells = 1.48, 95% CI = 1.38 to 1.59, P = .004); this effect, however, was not observed in H460 cells. The simultaneous addition of recombinant netrin-1 to H358 cells fully reversed apoptosis induction observed after netrin-1 siRNA transfection, indicating a specific role for netrin-1 in H358 cell survival. Similar effects of netrin-1 siRNA treatment were obtained with two other cell lines that expressed high levels of netrin-1 (H322 and A427); this siRNA had no effect on netrin-1 -low cell lines (H522 and H1435) ( Supplementary Figure 2 , A and B, available online).
We have recently shown that DCC-5Fbn, a 100 amino acid fragment of DCC, that contains the fi fth fi bronectin type III domain of DCC ( Figure 3, A ) affects the ability of netrin-1 to trigger multimerization of netrin-1 receptors and consequently inhibits the antiapoptotic effect of netrin-1 (22; F. Mille et al., unpublished). Addition of DCC-5Fbn to H358 cells triggered cell death, as measured by trypan blue exclusion assay, with the percentage of cell death in untreated cells was 8% and that in DCC5Fbn-treated cells was 26% (difference = 18%, 95% CI = 10% to 26%, P = .021). When the the MTT was used, the percentage of cells surviving in untreated cells being 100% and that in DCC5Fbn-treated cells being 51% (difference = 49%, 95% CI = 27% to 70%, P = .021), and when caspase-3 activity assay was used, the caspase-3 activity in DCC-5Fbn -treated cells normalized to that in untreated cells was 2.34 (difference = 1.34, 95% CI = 0.23 to 2.44, P = .049) ( Figure 3, B to D) . This cell death was related to netrin-1 expression because when H460 cells were used instead of H358 cells, DCC-5Fbn had no effect on these endpoints. Furthermore, addition of recombinant netrin-1 blocked the effect of DCC-5Fbn on cell death, as measured by the three assays mentioned above ( Figure 3, B to D) , and interleukin-3-receptor extracellular domain IL3R-EC (IL3R), a nonrelated recombinant protein of the same size and purifi ed under the same conditions as DCC-5Fbn, failed to trigger H358 cell death ( Figure 3, D ) . Similar results were obtained when two other netrin-1 -high cell lines (H322 and A427) were used instead of H358 cells, and no cell death was observed in 
Involvement of UNC5H and DAP-Kinase in H358 Lung Cancer Cell Death Induced by Netrin-1 Inhibition
We hypothesized that H358 cell death induced by the inhibition of the netrin-1 autocrine loop with netrin-1 siRNA or DCC-5Fbn occurred through UNC5H receptors because DCC is barely detectable in lung cancer cells ( Figure 1, D ) . To address this possibility, H358 cells were transfected with either a dominant negative mutant for DCC proapoptotic activity (DN DCC) or a dominant negative mutant for UNC5H proapoptotic activity (DN UNC5H), and cell death was analyzed in presence of either DCC-5Fbn or, as a control, the unrelated IL3R recombinant protein (IL3R). DN DCC expression failed to inhibit DCC-5Fbn -induced H358 cell death, with the percentage of cell death in DN-DCC -transfected cells in the presence of DCC-5Fbn being 34% and that in the absence of DCC5Fbn being 16% (difference = 18%, 95% CI = 12% to 24%, P = .049). However, expression of DN-UNC5H rendered H358 cells resistant to DCC-5Fbn ( Figure 4, A ) , indicating that UNC5H receptors are involved in DCC-5Fbn -induced cell death.
To determine which of the four UNC5H receptors initiated cell death in these cells, we targeted expression of each UNC5H -UNC5H1, UNC5H2, UNC5H3, or UNC5H4 -with siRNA under conditions in which cell death was induced with netrin-1 siRNA. None of the individual UNC5H siRNAs inhibited netrin-1 siRNA -mediated H358 cells apoptosis, suggesting that more than one of the UNC5H receptors have a role in cell death in the absence of netrin-1 ( Figure 4, B ) . In experiments that tested the effects of combinations of different siRNAs, we observed that a combination of siRNAs targeting UNC5H1 and UNC5H2 fully inhibited netrin-1 siRNA -mediated apoptosis (caspase-3 activity in cells treated with netrin-1 siRNA plus scrambled siRNA being 1.81 or plus UNC5H1 and UNC5H2 siRNAs being 1.02, normalized to caspase-3 activity in untreated cells [difference = 0.79, 95% CI = 0.54 to 1.04, P = .020]), whereas other combinations of two UNC5H siRNAs did not ( Figure 4, C ) . Thus, in human nonsmall cell lung tumors, netrin-1 -expressing lung cancer cells appear to increase their survival by inhibiting apoptosis induced by both UNC5H1 and UNC5H2 receptors.
To investigate the mechanism of cell death downstream of UNC5H receptors, we inhibited particular caspase activities. H358 cell death induced by netrin-1 siRNA treatment was blocked by expression of a dominant negative mutant of caspase-9 ( Figure 4, D ) , but expression of a dominant negative mutant of caspase-8 did not reverse the effect of netrin-1 targeting (with caspase-3 activity) in scrambled siRNA -treated H358 cells being 0.82 and that in netrin-1 siRNA -treated cells in the presence of DNC8 being 2.21, normalized to caspase-3 activity in untreated cells ([difference = 1.38, 95% CI = 0.34 to 2.42, P = .049]). Furthermore, netrin-1 siRNA -induced H358 cell death was inhibited by treatment with the potent general caspase inhibitor (z-VAD-fmk) and also with the caspase-3 or caspase-9 inhibitors (respectively, DEVD-fmk and LEHD-fmk), but no such effect was observed using the caspase-8 inhibitor (IETDfmk) ( Supplementary Figure 3 , available online). These observations are consistent with a requirement for caspase-9 -dependent signaling in UNC5H-induced cell death ( 9 ).
It has previously been reported that UNC5H2 triggers caspase-9 -dependent apoptosis via activation of DAP-kinase ( 15 ) . We assayed for DAP-kinase activation after DCC-5Fbn treatment or netrin-1 siRNA transfection by determining whether these treatments were associated with changes in DAP-kinase autophosphorylation (DAP-kinase activation depends directly on its dephosphorylation) ( 28 ) . DAP-kinase autophosphorylation was decreased after DCC-5Fbn treatment or netrin-1 siRNA transfection ( Supplementary Figure 4 , available online) but restored by a treatment with an excess of netrin-1 or by a combination of UNC5H1 and UNC5H2 siRNAs ( Supplementary Figure 4 , A, available online), indicating that the kinase is involved in the apoptotic pathway. DAPK1 gene expression was reduced in H460 cells ( Supplementary Figure 4 , B, available online), as previously reported ( 29 ) , indicating that in these cells with low expression of netrin-1, Apoptosis was monitored by measuring relative caspase-3 activity in presence of DCC-5Fbn or of an unrelated interleukin-3 receptor extracellular domain IL3R recombinant protein produced in the same conditions as DCC-5Fbn. Data are means of three independent experiments, each performed in duplicate. Error bars = upper 95% confi dence intervals. P values were calculated with a two-sided Mann -Whitney test, comparing treated samples with control. DCC = deleted in colorectal cancer.
the inhibition of netrin-1 dependence receptor pathway occurs downstream in the UNC5H-mediated death signaling pathway.
In Vivo Effect of Netrin-1 Autocrine Loop Disruption on Lung Tumor Progression
To determine whether interference with netrin-1 triggers tumor cell death in vivo, H358 or H460 cells were used to generate xenograft tumors in nude mice. When tumors reached a volume of 60 mm 3 , mice were treated daily by intratumor injection of either PBS (control) or 20 µ g of DCC-5Fbn for 25 days, and tumor volumes were determined for a period of 46 (H358) or 30 (H460) days. DCC-5Fbn fully inhibited tumor growth in H358 xenograft tumors in mice, with the mean volume on day 46 of PBS-treated tumors being 489 mm 3 and that of DCC-5Fbn -treated tumors being 84 mm 3 (difference = 404 mm , either scrambled or netrin-1 siRNA was injected intraperitoneally. The netrin-1 siRNA had no effect on tumor growth in mice with H460 xenograft tumors, but it fully inhibited tumor growth in mice with H358 xenograft tumors (mean tumor volume on day 22 of scrambled siRNAtreated mice being 427 mm 3 and that of netrin-1 siRNA -treated mice being 68 mm 3 ; difference = 359 mm 3 , 95% CI = 141 to 577 mm 3 , P = .016) ( Figure 5, C ) . To determine if the antitumor activity of DCC-5Fbn is associated with proapoptotic effects in vivo, we analyzed tumor cell death in mice carrying H358 or H460 xenograft tumors that had been treated (or not) with DCC-5Fbn for 15 days. Although the histology of DCC-5Fbn -and PBS-treated tumors was similar in mice carrying H460 tumors, a large central necrotic region was Figure 4 . Requirement of UNC5H and downstream apoptotic signaling in H358 cell death induced by netrin-1 inhibition. A ) Netrin-1 inhibition and cell death via UNC5H. H358 cells were transfected with a dominant negative mutant for DCC proapoptotic activity (DN DCC) or a dominant negative mutant for UNC5H proapoptotic activity (DN UNC5H). Upper : Western blots with anti-HA, anti-DCC, and anti-␤ -actin antibodies to detect DN UNC5H, DN DCC, and ␤ -actin, respectively. Lower : Cell death. Trypan blue exclusion assay was used to measure cell death after treatment with DCC-5Fbn alone, with recombinant netrin-1 in excess to reverse the effect of DCC5Fbn, or with an unrelated IL3R recombinant protein.
( B and C ) Requirement of UNC5H1 and UNC5H2 in cell death associated with netrin-1 inhibition. H358 cells were transfected with either scrambled siRNA or a netrin-1 siRNA plus one or more UNC5H siRNAs, and apoptosis was monitored by measuring caspase-3 activity. B ) One UNC5H siRNA. C ) Two to four UNC5H siRNAs. D ) Requirement of caspase-9 in cell death associated with netrin-1 inhibition. H358 cells were transfected with a dominant negative mutant for caspase-8 (DNC8) or caspase-9 (DNC9) in combination with either scrambled siRNA (siRNA scr.) or netrin-1 siRNA (siRNA net.). Upper : Western blots with anti-HA and anti-␤ -actin antibodies to detect DNC8 and/or DNC9 and ␤ -actin, respectively. Lower : Cell death quantifi ed by a caspase-3 assay. Data are means of three independent experiments. Error bars = upper 95% confi dence intervals. P values were calculated with a two-sided Mann -Whitney test; data were compared with the level of the control in panels ( A ) and ( D ) or with the level observed with netrin-1 siRNA in panels ( B ) and ( C ). DCC = deleted in colorectal cancer; siRNA = small interfering RNA; UNC5H = uncoordinated-5-homolog.
by guest on May 2, 2016 http://jnci.oxfordjournals.org/ Downloaded from observed in tumors of DCC-5Fbn -treated mice carrying H358 xenograft tumors ( Figure 6, A ) . To address the role of apoptosis in this antitumor effect, we used a TUNEL assay and detected active caspase-3 by immunostaining ( Figure 6 , A ) on sections from tumors that had been treated with DCC-5Fbn or PBS. Although DCC-5Fbn had no effect on H460 tumor cell death, there was a statistically signifi cant increase in apoptotic tumor cell death in H358 tumors. The increased apoptosis in DCC-5Fbn -treated H358 tumors was not only detected on tumors ' cryosections ( Figure 6 , A ) but also by direct measurement of caspase-3 activity in the tumors ( Figure 6 , B ) (caspase-3 activity, normalized to that in PBS-treated tumors, in DCC-5Fbn -treated tumors = 2.54; difference = 1.54, 95% CI = 0.73 to 2.35, P < .05). Thus, DCC5Fbn -induced tumor growth inhibition appears to be associated with increased tumor cell apoptosis.
Discussion
We provide here the first demonstration that a large fraction of primary NSCLC tumors overexpress netrin-1, the ligand of the dependence receptors DCC and UNC5H, and that this expression confers a selective advantage for tumor cell survival. We then propose that interference with netrin-1 could be an innovative anticancer strategy.
The dependence receptors ' concept predicts that the fi ne balance between netrin-1 level and DCC and/or UNC5H level may control development, as well as adult tissue remodeling and homeostasis ( 7 ) . We have demonstrated that the loss of this apoptosismediated regulatory function in the adult is involved in breast and intestinal tumor initiation and progression ( 22 , 30 ) . Inhibition of apoptosis occurs by either a decrease in the levels of the receptors [eg, DCC and UNC5H expression is lost in the majority of colorectal cancers ( 17 , 19 ) ] or overexpression of netrin-1.
We have recently demonstrated ( 22 ) that overexpression of netrin-1 confers a selective advantage for tumor cell survival in metastatic breast cancer, and Link et al. ( 31 ) have observed that netrin-1 overexpression is associated with worse outcome in poorly differentiated pancreatic adenocarcinomas. Similar to development of the mammary gland and the pancreas, lung development requires branching morphogenesis, and netrin-1 and its receptors have been proposed to have an important role during lung development, possibly by regulating branching ( 30 , 32 , 33 ) . Thus, it may be worth noting that our results in lung tumor -cultured cell lines and in primary NSCLC tumors support the view that, rather than losing expression of netrin-1 receptors as observed in colorectal cancers, a large fraction of non -small cell lung tumors appear to overexpress netrin-1. It appears that the elevated netrin-1 level is a selective advantage acquired by lung cancer epithelial cells that permits them to escape apoptosis induced by netrin-1 dependence receptors and, consequently, to survive independently of netrin-1 availability. We found that UNC5H receptors were critical for netrin-1 dependence: DCC was often barely detectable in the tested lung tumors, and ablation of both UNC5H1 and UNC5H2 in netrin-1 -high H358 cells was suffi cient to antagonize the proapoptotic stimulus generated by netrin-1 inhibition.
As predicted by the dependence receptor model, our results suggest that a lung tumor cell can escape the dependence receptor system in at least three ways: 1) through a decrease in the level of the receptors ( 16 , 17 ) ; 2) by inhibition of the downstream signaling pathways (the serine/threonine DAP-kinase, which mediates UNC5H-induced cell death, is also known to be frequently downregulated by promoter methylation in NSCLC) ( 34 ) ; and 3), as shown in this study, by endogenous expression of netrin-1. It is unclear why some breast tumors ( 22 ) and a large fraction of lung tumors overexpress netrin-1, but most colorectal tumors lose the receptors (only 7% of colorectal cancers show an increase in netrin-1 expression) ( 19 , 35 ) . A possible explanation is that netrin-1 expression not only confers a gain in survival on the lung tumor cells but may also lead to enhancement of nonapoptotic signaling by netrin-1 receptors.
The role of netrin-1 in nonapoptotic signaling in the adult is not known with certainty. Netrin-1 was shown to bind a complex that includes some integrins ( 36 ) , and thus, it is conceivable that netrin-1 overexpression triggers the activation of ␣ 6 ␤ 4/ ␣ 3 ␤ 1 integrins expressed by lung epithelial cells. These integrins regulate cell migration and invasiveness and therefore may have a role in cancer progression ( 37 ) . It is also possible that netrin-1 is an angiogenic factor that promotes tumor vasculature as netrin-1 was recently proposed to play a role in embryonic angiogenesis, although this hypothesis is controversial ( 38 -41 ) . Alternatively, because endogenous netrin-1 expression inhibits proapoptotic signaling by all dependence receptors, it may have more potent effects on survival than the loss of one or two netrin-1 receptors. At a genetic or epigenetic level, the decrease in the expression of dependence receptors occurs through loss of heterozygosity or promoter methylation ( 17 , 19 , 42 ) ; the mechanism allowing netrin-1 upregulation is unknown.
These observations provide not only evidence for the importance of ligand -dependence receptors pairs in the regulation of tumor development but also a new therapeutic strategy. Advanced NSCLC is the leading cause of cancer-related deaths in the world. Most patients with advanced NSCLC present with metastatic disease and have a median survival after diagnosis of 4 -5 months in absence of treatment. Combination of cytotoxic chemotherapies results in a modest increase in survival. The development and clinical application of novel drugs that specifi cally target altered signaling pathways in this complex and heterogeneous disease are therefore required, and targeting netrin-1 may then be attractive.
Our study has, however, some limitations. It should indeed be noted that induction of apoptotic death in netrin-1 -producing cells by interfering with netrin-1 is thus far restricted to human cell lines and animal models. Because these cells and these models fail to recapitulate the process of NSCLC in humans and its diversity, it is unclear whether a treatment based on interference with netrin-1 or other strategies based on preventing the interaction between netrin-1 and its receptors will be effi cient alternative targeted strategies.
In conclusion, our fi ndings raise the possibility that a targeted treatment that is based on inhibition of the interaction between netrin-1 and its dependence receptors might be of benefi t to patients suffering from lung cancer whose primary tumors show high netrin-1 expression. Additional preclinical and clinical studies will be needed to determine whether anticancer treatments based on netrin-1 -receptors interference represent viable alternative therapeutic approaches. Figure 6 . Effect of netrin-1 autocrine loop disruption on lung tumor histology and cell death in vivo. Cryosections were prepared from tumors from mice carrying H358 or H460 xenograft tumors that were treated for 15 days with either PBS or the DCC fragment DCC-5Fbn. A ) Histology. Top : Hematoxylin -eosin staining. *Large necrotic lesion area in a DCC-5Fbn -treated H358-derived tumor. Middle : TUNEL. Lower : Anti-caspase-3 immunostaining. B ) Quantifi cation of apoptosis by caspase-3 activity assay on xenografts ' lysates analyzed after 2 days of treatment (after the tumors reached a palpable size). Data are means of caspase-3 activities in three xenograft tumor lysates for each condition. Error bars = upper 95% confi dence intervals. P values were calculated with a two-sided Mann -Whitney test, and data are compared with level in PBS-treated tumors. DCC = deleted in colorectal cancer; PBS = phosphate-buffered saline; TUNEL = terminal deoxynucleodityltransferase -mediated dUTPbiotin nick end labeling.
